OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Cystic Fibrosis is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
P402 Separation anxiety or a Kaftrio side effect? Implementation of cognitive behavioural therapy strategies with a young child with cystic fibrosis (CF): A clinical case study	285
P408 The halo effect in cystic fibrosis: when educated patients in turn educate their family carers	132
EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?	103
P131 Effect of deprescribing from inhaled corticosteroids in people with cystic fibrosis: challenges & opportunities for a target trial emulation using the UK CF Registry	96
WS08.03 How does elexacaftor/tezacaftor/ivacaftor affect improvement in exercise capacity and body composition in adults with cystic fibrosis who have completed an exercise intervention?	96
P296 Characteristics of carbohydrate metabolism disorders in children with cystic fibrosis in the Moscow region	90
WS13.03 Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del	83
P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study	83
EPS10.06 Highly-effective CFTR modulation is associated with greater height and peak lung function in children with cystic fibrosis	76
EPS8.02 Evolving physiotherapy airway clearance technique (ACT) interventions during cystic fibrosis (CF) pregnancy in the variant specific therapy (VST) era	71
P172 Oscillometry: assessment of bronchial obstruction in children with cystic fibrosis	70
P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation	64
P227 Life threatening infection with a highly resistant Achromobacter xylosoxidans strain	60
Using heart rate data from wrist worn activity trackers to define thresholds for moderate to vigorous physical activity in children and young people with cystic fibrosis	60
P024 Analysis of the effect of cytochrome P450 genes polymorphism on the efficacy and safety of CFTR modulator therapy in cystic fibrosis	59
P478 Multiple breath inert gas wash out in infants and toddlers with cystic fibrosis before and after initiating inhaled hypertonic saline	58
Treatment of intestinal and liver features in cystic fibrosis mice by the osmotic laxative polyethylene glycol	57
“Mind the gap”- will we ever see equal median predicted survival for males and females in cystic fibrosis?	53
Contents	51
WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years	50
346 Leaky gut, dysbiosis, and inflammation support inter-organ communication in cystic fibrosis	50
258 Functional correction of CFTR-G542X in human bronchial epithelial cells using a Type I CRISPR adenine base editor with a guide-length- tunable editing window	47
97 Separability of membrane permeabilization and cell killing activities of the human host defense peptide LL-37 in Pseudomonas aeruginosa	47
652 Proteomics of bronchoalveolar lavage fluid in cystic fibrosis ferrets spontaneously colonized by Pseudomonas aeruginosa	45
252 Model systems to define tool LNP vehicles for the development of next generation therapies for Cystic Fibrosis	44

41 Loss of MexEF-OprN function increases virulence of clinical Pseudomonas aeruginosa isolates	44
78 Pseudomonas aeruginosa induced GM-CSF production by airway epithelial cells could help protect against Mycobacterium abscessus	42
634 Evaluating shared decision making in lung transplant discussions between clinicians and people with severe CF	42
523 Navigating school with cystic fibrosis: perspectives of people with CF and their caregivers	41
748 Development of metabolic syndrome in people with cystic fibrosis after three years of elexacaftor/tezacaftor/ivacaftor	41
496 Pilot and feasibility study of an individualized telehealth exercise program in CF patients	41
729 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on healthcare resource utilization (HCRU) over three years in LONGITUDE – a UK CF Registry observational study	41
757 The impacts of highly effective modulator therapy and telehealth on cystic fibrosis care: Changes in visit frequency	40
379 Identifying and prioritizing burdens of cystic fibrosis care for Canadians living with CF	40
475 Physiologically based pharmacokinetic of elexacaftor/tezacaftor/ ivacaftor in children with cystic fibrosis: extrapolation of the dosing regimen in children under 2 years of age	40
279 Simultaneous inhibition of DNA-PKcs and 53BP1 enables the enrichment-free replacement of the CFTR cDNA in airway basal stem cells	40
34 Regulation of an epoxide-based virulence factor in Pseudomonas aeruginosa	37
48 Small airway epithelial cells in M. abscessus infection: Implications for inflammation and epithelial barrier integrity	37